Table 1.
Patients' characteristics.
| n = 86 MS patients | |||
|---|---|---|---|
| Diagnosis | RRMS | PMS | Controls (OND) |
| Number (n) | 47 (44%) | 39 (37%) | 20 (100%) |
| Female (n) | 29 (62%) | 21 (54%) | 13 (65%) |
| Age (years) | 34 (27–47) | 53 (47–59) | 44 (27–51) |
| Recent relapse* | 26 (55 %) | 0 | n/a |
| EDSS | 2.0 (1.5–4.0) | 6.0 (4.0–7.0) | n/a |
| DMT at LP | 7 | 3 | n/a |
| GFAP (pg/ml) (27) | |||
| CSF | 6836 (4,695–10,654) | 11,131 (7,459–14,740) | 6158 (2,425–8,064) |
| Serum | 107 (74–141) | 131 (98.6–224) | 92.3 (57.2–140) |
| NfL (pg/ml) (27) | |||
| CSF | 1612 (871–3,205) | 1,450 (1,045–2,340) | 585 (358–835) |
| Serum | 14.6 (9.2–26.8) | 19.9 (13.9–28.4) | 9.2 (6.0–12.3) |
| CHI3L1 (ng/ml) | |||
| CSF | 124 (88.3–162) | 181.0 (151–254) | 74.4 (47.5–96.1) |
| Serum | 26.4 (21.4–35.4) | 35.6 (23.8–96.3) | 25.8 (21.7–43.2) |
Numbers are given as median and IQR or percentages in brackets.
*
A recent relapse was defined as focal neurological disturbance lasting more than 24 h, without an alternate explanation.
RRMS, relapsing–remitting MS; PMS, progressive MS; PPMS, primary progressive MS; OND, other neurological diseases; EDSS, expanded disability status scale; DMT, disease-modifying treatment; LP, lumbar puncture.